8-K
Niagen Bioscience, Inc. (NAGE)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 6, 2020
CHROMADEX CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 001-37752 | 26-2940963 |
|---|---|---|
| (State<br>or other jurisdiction of incorporation) | (Commission<br>File Number) | (IRS<br>Employer Identification No.) |
10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024
(Address of principal executive offices, including zip code)
(310) 388-6706
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title<br>of each class | Trading<br>Symbol(s) | Name of<br>each exchange on which registered |
|---|---|---|
| Common<br>Stock, par value $0.001 per share | CDXC | The<br>Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
ChromaDex Corporation (the “Company” or “ChromaDex”) recently became aware that, due to an administrative error, certain of the Company’s previously filed Annual Reports on Form 10-K, including the Annual Report on Form 10-K for the year ended December 31, 2019, as amended, contained the wrong filing, issued and/or expiration dates with respect to certain of the Company’s owned and licensed patents. The following table sets forth the Company’s existing owned and licensed patents with such filing, issued and/or expiration dates as corrected:
| Patent Number | Title | Filing Date | Issued Date | Expires | Licensor |
|---|---|---|---|---|---|
| 7,205,284 | Potent<br>immunostimulants from microalgae | 7/10/2001 | 4/17/2007 | 3/9/2022 | Licensed<br>from University of Mississippi |
| 7,776,326 | Methods<br>and compositions for treating neuropathies | 6/3/2005 | 8/17/2010 | 6/24/2026 | Licensed<br>from Washington University |
| 7,846,452 | Potent<br>immunostimulatory extracts from microalgae | 7/28/2005 | 12/7/2010 | 7/28/2025 | Licensed<br>from University of Mississippi |
| 8,106,184 | Nicotinyl<br>Riboside Compositions and Methods of Use | 11/17/2006 | 1/31/2012 | 9/20/2027 | Licensed<br>from Cornell University |
| 8,114,626 | Yeast<br>strain and method for using the same to produce Nicotinamide<br>Riboside | 3/26/2009 | 2/14/2012 | 1/5/2026 | Licensed<br>from Dartmouth College |
| 8,133,917 | Pterostilbene<br>as an agonist for the peroxisome proliferator-activated receptor<br>alpha isoform | 10/25/2010 | 3/13/2012 | 8/18/2025 | Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture |
| 8,197,807 | Nicotinamide<br>Riboside Kinase compositions and Methods for using the<br>same | 4/20/2006 | 6/12/2012 | 11/19/2026 | Licensed<br>from Dartmouth College |
| 8,252,845 | Pterostilbene<br>as an agonist for the peroxisome proliferator-activated receptor<br>alpha isoform | 2/1/2012 | 8/28/2012 | 8/18/2025 | Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture |
| 8,318,807 | Pterostilbene<br>Caffeine Co-Crystal Forms | 7/30/2010 | 11/27/2012 | 7/21/2031 | Licensed<br>from Laurus Labs Private Limited |
| 8,383,086 | Nicotinamide<br>Riboside Kinase compositions and Methods for using the<br>same | 4/12/2012 | 2/26/2013 | 4/20/2026 | Licensed<br>from Dartmouth College |
| 8,399,712 | Pterostilbene<br>cocrystals | 7/30/2010 | 3/19/2013 | 8/10/2031 | Licensed<br>from Laurus Labs Private Limited |
| --- | --- | --- | --- | --- | --- |
| 8,524,782 | Key<br>intermediate for the preparation of Stilbenes, solid forms of<br>Pterostilbene, and methods for making the same | 1/21/2011 | 9/3/2013 | 2/1/2030 | Licensed<br>from Laurus Labs Private Limited |
| 8,809,400 | Method<br>to Ameliorate Oxidative Stress and Improve Working Memory Via<br>Pterostilbene Administration | 8/8/2011 | 8/19/2014 | 10/2/2028 | Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture |
| 8,841,350 | Method<br>for treating non-melanoma skin cancer by inducing<br>UDP-Glucuronosyltransferase activity using<br>pterostilbene | 5/8/2012 | 9/23/2014 | 5/8/2032 | Co-owned<br>by ChromaDex and University of California |
| 8,889,126 | Methods<br>and compositions for treating neuropathies | 5/28/2010 | 11/18/2014 | 6/3/2025 | Licensed<br>from Washington University |
| 9,000,147 | Nicotyl<br>riboside compositions and methods of use | 1/17/2012 | 4/7/2015 | 11/17/2026 | Licensed<br>from Cornell University |
| 9,028,887 | Method<br>improve spatial memory via pterostilbene<br>administration | 5/22/2014 | 5/12/2015 | 6/10/2028 | Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture |
| 9,295,688 | Methods<br>and compositions for treating neuropathies | 10/10/2014 | 3/29/2016 | 6/3/2025 | Licensed<br>from Washington University |
| 9,321,797 | Nicotyl<br>riboside compositions and methods of use | 11/17/2014 | 4/26/2016 | 11/17/2026 | Licensed<br>from Cornell University |
| 9,439,875 | Anxiolytic<br>effect of pterostilbene | 5/11/2011 | 9/13/2016 | 12/11/2031 | Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture |
| 9,975,915 | Crystalline<br>forms of nicotinoyl ribosides, modified derivatives thereof, and<br>phosphorylated analogs thereof, and methods of preparation<br>thereof | 11/10/2017 | 5/22/2018 | 11/10/2037 | Co-owned<br>by ChromaDex and The Queen’s University of<br>Belfast |
| 10,000,519 | Methods of Preparing Nicotinamide Riboside and Derivatives<br>Thereof | 7/24/2014 | 6/19/2018 | 7/24/2034 | Licensed from The Queen’s University of<br>Belfast |
| 10,000,520 | B-vitamin<br>and amino acid conjugates ofnicotinoyl ribosides and reduced<br>nicotinoyl ribosides, derivatives thereof, and methods of<br>preparation thereof | 3/16/2017 | 6/19/2018 | 3/16/2037 | Co-owned<br>by ChromaDex and The Queen’s University of<br>Belfast |
| 10,183,036 | Use of nicotinic acid riboside or nicotinamide riboside<br>derivatives, and reduced derivatives thereof, as NAD+ increasing<br>precursors | 4/20/2017 | 1/22/2019 | 4/20/2037 | Owned by ChromaDex |
| 10,280,190 | Nicotinic acid riboside or nicotinamide riboside compositions,<br>reduced derivatives thereof, and the use thereof to enhance skin<br>permeation in treating skin conditions | 3/16/2016 | 5/7/2019 | 5/31/2036 | Co-owned by ChromaDex and The Queen’s University of<br>Belfast |
| 10,688,118 | Nicotinamide riboside compositions for topical use in treating skin<br>conditions | 10/30/2014 | 6/23/2020 | 4/6/2035 | Owned by ChromaDex |
| 10,689,411 | Efficient and scalable syntheses of nicotinoyl ribosides and<br>reduced nicotinoyl ribosides, modified derivatives thereof,<br>phosphorylated analogs thereof, adenylyl dinucleotide conjugates<br>thereof, and novel crystalline forms<br>thereof | 11/10/2017 | 6/23/2020 | 11/10/2037 | Co-owned by ChromaDex and The Queen’s University of<br>Belfast |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CHROMADEX CORPORATION | ||
|---|---|---|
| Dated:<br>July 8, 2020 | ||
| By: | /s/<br>Kevin M.<br>Farr | |
| Name:<br>Kevin M. Farr | ||
| Chief<br>Financial Officer |